Office of Chief Scientist, Office of Critical Path Programs, US Food and Drug Administration, Silver Spring, Maryland 20903, USA.
Int J Tuberc Lung Dis. 2011 Jul;15(7):985-7. doi: 10.5588/ijtld.10.0712.
High costs and limited returns on investment have hampered progress in developing new diagnostic tests and treatments for tuberculosis (TB). We need new biomarkers to develop assays that can rapidly, efficiently and reliably detect Mycobacterium tuberculosis infection and disease, identify drug resistance and expedite drug and vaccine development. This can only be accomplished through cross-disciplinary collaborations to facilitate access to human specimens. The Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health, the industry and academia experts came together in a June 2010 workshop to examine the field of TB diagnostic test development and biomarker discovery, identify areas of most urgent need and formulate strategies to address those needs.
高昂的成本和有限的投资回报阻碍了结核病（TB）新诊断测试和治疗方法的发展。我们需要新的生物标志物来开发能够快速、高效和可靠地检测结核分枝杆菌感染和疾病、识别耐药性并加速药物和疫苗开发的检测方法。这只能通过跨学科合作来实现，以方便获取人体标本。美国食品和药物管理局、疾病控制和预防中心、美国国立卫生研究院、工业界和学术界的专家于 2010 年 6 月举行了一次研讨会，以检查结核病诊断测试开发和生物标志物发现领域，确定最紧迫的需求领域，并制定解决这些需求的策略。
